Treatment of Severe Unconjugated Hyperbilirubinemia with Phenobarbitone in Two First-Degree Siblings with Crigler-Najjar Syndrome (CNS) Type 2: A Success Story
DOI:
https://doi.org/10.58427/apghn.4.4.2025.201-207Keywords:
crigler-najjar syndrome type 2, gene therapy, neonatal jaundice, phenobarbitoneAbstract
Background: Crigler–Najjar syndrome (CNS) type 2 is a rare autosomal recessive disorder of bilirubin conjugation caused by mutations in the UGT1A1 gene. It presents in infancy with unconjugated hyperbilirubinemia that does not respond to phototherapy but improves with phenobarbitone, which enhances residual enzyme activity. Although phenobarbitone remains the cornerstone of treatment, familial recurrence of CNS type 2 is rarely reported in pediatric literature.
Case: We report two siblings born to consanguineous parents who presented with progressive jaundice during early infancy. The first child, a 2-month-old boy, had multiple hospitalisations for phototherapy without benefit. Laboratory evaluation revealed total bilirubin of 31 mg/dL with normal liver function and no evidence of hemolysis. Genetic testing confirmed a homozygous UGT1A1 (c.1456T>G; p.Tyr486Asp) mutation. He was treated with phenobarbitone (5–8 mg/kg/day) and calcium phosphate, achieving a bilirubin level <10 mg/dL within 4 weeks. Three years later, his younger sister developed similar unconjugated jaundice from day 4 of life and harboured the same mutation; she responded well to phenobarbitone alone. Both siblings remain well on long-term follow-up.
Discussion: This case highlights the genetic basis and favorable response of CNS type 2 to phenobarbitone, which induces hepatic UGT1A1 expression. Familial clustering of CNS 2, though reported in few global studies, is seldom documented from India.
Conclusion: Early genetic diagnosis, timely institution of phenobarbitone, and family counselling are critical for successful management of CNS type 2. These cases reaffirm the long-term safety and efficacy of phenobarbitone in familial presentations of this rare disorder.
References
Bosma PJ. Inherited disorders of bilirubin metabolism. J Hepatol. 2003;38(1):107-17. https://doi.org/10.1016/s0168-8278(02)00359-8 DOI: https://doi.org/10.1016/S0168-8278(02)00359-8
Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (ugt1a1) causing crigler-najjar and gilbert syndromes: Correlation of genotype to phenotype. Hum Mutat. 2000;16(4):297-306. https://doi.org/10.1002/1098-1004(200010)16:4<297::Aid-humu2>3.0.Co;2-z DOI: https://doi.org/10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z
Tcaciuc E, Podurean M, Tcaciuc A. Management of crigler-najjar syndrome. Med Pharm Rep. 2021;94(Suppl No 1):S64-s7. https://doi.org/10.15386/mpr-2234
Kumar P, Sasmal G, Gupta S, Saxena R, Kohli S. Crigler najjar syndrome type 2 (cns type 2): An unwonted cause of jaundice in adults. J Clin Diagn Res. 2017;11(7):Od05-od6. https://doi.org/10.7860/jcdr/2017/28195.10221 DOI: https://doi.org/10.7860/JCDR/2017/28195.10221
Aarti B, Bhattacharya A, Shamima, Gupta S. Hereditary hyperbilirubinemia: An original study of four cases with review of literature. IOSR Journal of Dental and Medical Sciences. 2014;13:38-42. https://doi.org/10.9790/0853-131113842 DOI: https://doi.org/10.9790/0853-131113842
Strauss KA, Ahlfors CE, Soltys K, Mazareigos GV, Young M, Bowser LE, et al. Crigler-najjar syndrome type 1: Pathophysiology, natural history, and therapeutic frontier. Hepatology. 2020;71(6):1923-39. https://doi.org/10.1002/hep.30959 DOI: https://doi.org/10.1002/hep.30959
Sambati V, Laudisio S, Motta M, Esposito S. Therapeutic options for crigler-najjar syndrome: A scoping review. Int J Mol Sci. 2024;25(20). https://doi.org/10.3390/ijms252011006 DOI: https://doi.org/10.3390/ijms252011006
Lin Q, Zhu D, Chen C, Feng Y, Shen F, Wu Z. Risk factors for neonatal hyperbilirubinemia: A systematic review and meta-analysis. Transl Pediatr. 2022;11(6):1001-9. https://doi.org/10.21037/tp-22-229 DOI: https://doi.org/10.21037/tp-22-229
Crigler JF, Jr., Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics. 1952;10(2):169-80.
Khedr M, Behairy B, Basiouny H, Zeitoon N, Elfert A, Zakaria H, Ammar T. Clinical and molecular study of egyptian pediatric patients with crigler-najjar syndrome. Egyptian Liver Journal. 2025;15. https://doi.org/10.1186/s43066-025-00428-w DOI: https://doi.org/10.1186/s43066-025-00428-w
Kovačić Perica M, Todorić I, Marčinković N, Džepina P, Aničić MN, Mrzljak A, Vuković J. Case report: Crigler-najjar syndrome type 1 in croatia-more than a one in a million: A case series. Front Pediatr. 2023;11:1276349. https://doi.org/10.3389/fped.2023.1276349 DOI: https://doi.org/10.3389/fped.2023.1276349
Petit FM, Bézieau S, Gajdos V, Parisot F, Scoul C, Capel L, et al. The tunisian population history through the crigler-najjar type i syndrome. Eur J Hum Genet. 2008;16(7):848-53. https://doi.org/10.1038/sj.ejhg.5201989 DOI: https://doi.org/10.1038/sj.ejhg.5201989
Nair KM, Lohse P, Nampoothiri S. Crigler-najjar syndrome type 2: Novel ugt1a1 mutation. Indian J Hum Genet. 2012;18(2):233-4. https://doi.org/10.4103/0971-6866.100776 DOI: https://doi.org/10.4103/0971-6866.100776
Ghorui A, Chowdhry BK, Manjhi PK, Kumar P, Kumar CM. Evaluation of efficacy of oral calcium phosphate as an adjunct to standard-of-care regular phototherapy in cases of neonatal jaundice: A hospital-based double-blind, randomised, placebo-controlled trial. BMJ Paediatr Open. 2024;8(1). https://doi.org/10.1136/bmjpo-2024-002902 DOI: https://doi.org/10.1136/bmjpo-2024-002902
Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J, et al. Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in japanese patients with crigler-najjar syndrome or gilbert's syndrome as well as in healthy japanese subjects. J Gastroenterol Hepatol. 2004;19(9):1023-8. https://doi.org/10.1111/j.1440-1746.2004.03370.x DOI: https://doi.org/10.1111/j.1440-1746.2004.03370.x
Sun L, Li M, Zhang L, Teng X, Chen X, Zhou X, et al. Differences in ugt1a1 gene mutations and pathological liver changes between chinese patients with gilbert syndrome and crigler-najjar syndrome type ii. Medicine (Baltimore). 2017;96(45):e8620. https://doi.org/10.1097/md.0000000000008620 DOI: https://doi.org/10.1097/MD.0000000000008620
Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, Guillemette C. Common human ugt1a polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (sn-38). Mol Pharmacol. 2002;62(3):608-17. https://doi.org/10.1124/mol.62.3.608 DOI: https://doi.org/10.1124/mol.62.3.608
Yu Y, Fisher JE, Lillegard JB, Rodysill B, Amiot B, Nyberg SL. Cell therapies for liver diseases. Liver Transpl. 2012;18(1):9-21. https://doi.org/10.1002/lt.22467 DOI: https://doi.org/10.1002/lt.22467
Ambrosino G, Varotto S, Strom SC, Guariso G, Franchin E, Miotto D, et al. Isolated hepatocyte transplantation for crigler-najjar syndrome type 1. Cell Transplant. 2005;14(2-3):151-7. https://doi.org/10.3727/000000005783983250 DOI: https://doi.org/10.3727/000000005783983250
D'Antiga L, Beuers U, Ronzitti G, Brunetti-Pierri N, Baumann U, Di Giorgio A, et al. Gene therapy in patients with the crigler-najjar syndrome. N Engl J Med. 2023;389(7):620-31. https://doi.org/10.1056/NEJMoa2214084 DOI: https://doi.org/10.1056/NEJMoa2214084
Published
Issue
Section
License
Copyright (c) 2025 Sachin Kumar, Siddhavatam Rahul Karthik, Gandharav Pahuja, Sarthak Chakrabarti, Prateek Kumar Panda, Indar Kumar Sharawat
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
